RxDoctor Payments Data

Robyn Halbrook, NP

Family · Sugar Land, TXNPI 1669807376

Payments from drug & device makers

$2,483in general payments, 2019–2025

Across 201 payments — averaging $12.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$954
  • Urovant Sciences Inc$540
  • Astellas Pharma US Inc$371
  • AbbVie$326
  • Convatec Inc.$105
  • Axonics, Inc.$81
  • plus $105 from 4 others

What the payments were for

  • Food & beverage$2,30893%
  • Education$1757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,483 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$63,870
Medicare patients
312
Services billed
1,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron291$192,964
MyrbetriqMirabegron239$175,878
ElmironPentosan Polysulfate Sodium12$7,977
Solifenacin Succinate180$7,097
Mirabegron ErMirabegron14$6,478
Methenamine Hippurate91$5,652
PremarinEstrogens, Conjugated11$5,371
Tolterodine Tartrate ErTolterodine Tartrate43$4,742
Estradiol45$3,204
Trospium Chloride ErTrospium Chloride17$1,466
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst95$1,227
Fesoterodine Fumarate ErFesoterodine Fumarate16$1,217
Trimethoprim22$692
Cephalexin134$602
Trospium Chloride21$584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$954$192,964291 claims
Astellas Pharma US IncMyrbetriq$371$175,878239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →